Voyager Therapeutics adds proof its gene therapy for Parkinson’s can work, shares soar – Endpoints News
Endpoints News |
Voyager Therapeutics adds proof its gene therapy for Parkinson’s can work, shares soar
Endpoints News The Cambridge, MA-based biotech has fleshed out its early-stage proof-of-concept data on VY-AADC01, offering new data that demonstrate a heightened efficacy for two higher doses of the gene therapy. Executives at Voyager tell me that they’re heartened … Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …GlobeNewswire (press release) Voyager Therapeutics (VYGR) Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …StreetInsider.com Voyager’s VY-AADC01 shows encouraging results in early-stage Parkinson’s study; shares ahead 27% premarketSeeking Alpha |
|
Global Updated Gene Therapy Technologies, Markets and …
Business Wire (press release) The “Gene Therapy – Technologies, Markets and Companies” report from Jain PharmaBiotech has been added to Research and Markets’ offering. Th. |
KCUR |
Shawnee Woman Was Among First In The World To Undergo New FDA-Approved Cancer Therapy
KCUR CAR: It’s a mouthful, but it stands for chimeric antigen receptors. The therapy involves removing a patient’s T cells, a type of white blood cell, and genetically engineering them to recognize and attack the patient’s tumors. The T cells are then put … |
PR Web |
Stem Cell Assay Market – Industry Analysis, Size, Share, Growth, Trends, and Outlook to 2025
Medgadget (blog) Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected … Robert Russell Named Director of Physician Engagement at Okyanos Center for Regenerative MedicinePR Web (press release) |
Labiotech.eu (blog) |
The CAR–T Race is Far from Over: This CEO is Exploring a New Avenue
Labiotech.eu (blog) Gilead has just splashed out $12 billion for Kite Pharma, and Ihe FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR–T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech … |
Labiotech.eu (blog) |
The CAR–T Race is Far from Over: This CEO is Exploring a New Avenue
Labiotech.eu (blog) Gilead has just splashed out $12 billion for Kite Pharma, and Ihe FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR–T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech … |